PTGER1 and stroke disorder: The similar relative effect of SC-51089 on behavioral and anatomical outcomes of experimental stroke and excitotoxicity compared to controls [19], [23], [31], [40] was observed in the study with another EP1 receptor antagonist, ONO-8713, in similar experimental conditions [32], and these outcomes were comparable to the outcomes measured in the EP1−/− mice with and without drug treatment, suggesting appropriate SC-51089 bioavailability with the treatment regimen used in this study.